













792Reduced-Intensity Conditioning Hematopoietic Stem
Cell Transplantation in Patients Over 60 Years:
Hematologic Malignancy Outcomes Are Not Impaired
in Advanced Age
John Koreth,1 Julie Aldridge,2 Haesook T. Kim,2 Edwin P. Alyea, III,1 Corey Cutler,1
Philippe Armand,1 Jerome Ritz,1 Joseph H. Antin,1 Robert J. Soiffer,1 Vincent T. Ho1Reduced-intensity-conditioning (RIC) hematopoietic stem cell transplantation (HSCT) is markedly underu-
tilized in the elderly, in part because the impact of advanced age on outcomes is poorly understood. We ret-
rospectively analyzed outcomes in 158 consecutive hematologic malignancy patients aged $60 years
(median, 63 years; range: 60-71 years) undergoing fludarabine/busulfan-based RIC, with a median-follow-
up of 34 months (range: 12.0-85.7). Multivariate analysis was undertaken for factors having an impact on out-
come. For the patients aged$60 years, 2-year nonrelapse mortality (NRM) and relapse was 10% and 54.6%,
respectively. Two-year overall and progression-free survival (OS, PFS) was 46% and 35%, respectively. Grade
II-IV acute and chronic graft-versus-host disease (aGVHD, cGVHD) incidence was 19.6% and 45.9%, respec-
tively. Comparing 110 patients aged 60-64 years versus 48 patients aged$65 years, 2-year NRM and relapse
was 10.5% versus 8.3% (P 5 .84) and 53.5% versus 56.3% (P 5 .31), respectively. Grade II-IV aGVHD
and cGVHD incidence was 19.1% versus 22.9% (P 5 .52) and 51.8% versus 32.5% (P 5 .01), respectively.
Two-year OS and PFS was 49% versus 41% (P 5 .11) and 36% versus 35% (P 5 .24), respectively. In a multi-
variate Cox-model, high-risk disease associated with poorer PFS (hazard ratio [HR]5 2.1, P 5 .01) and OS
(HR5 1.84, P5.03); acute myelogenous leukemia/myelodysplastic syndrome diagnosis (HR5 1.66, P5.03)
and matched-related donor (HR 5 1.62, P 5 .03) associated with poorer PFS. RIC HSCT is well tolerated,
with reasonable survival in elderly patients. Age is not associated with impaired outcomes. HSCT should not
be excluded solely based on advanced patient age.
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The incidence of hematologic malignancies rises
with age. For instance, acute myelogenous leukemia
(AML) has a 10-fold greater incidence in adults aged
$65 years compared to adults aged 20-44 years [1,2].
Survival is also markedly impaired in elderly AML pa-
tients aged$60 years, even for relatively healthy older1Division of Hematologic Malignancies, Dana Farber
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6/j.bbmt.2009.12.537patients enrolled in acute leukemia cooperative group
chemotherapy trials [1,3]. Impaired survival in older pa-
tients is because of increased chemotherapy-related tox-
icity and adverse disease biology [3]. Similarly, with
regard to primary myelodysplastic syndrome (MDS),
75% of patients are aged$60 years. Stratified by Inter-
national Prognostic Scoring System (IPSS) risk, sur-
vival for older patients with low and intermediate-1
IPSS-risk MDS is markedly impaired compared to
those aged\60 years [4]. Elderly patients aged $60
years also have disproportionately impaired outcomes
in acute lymphoblastic leukemia (ALL), Hodgkin
(HL) and non-Hodgkin lymphomas (NHL) [5-10].
Reduced-intensity conditioning (RIC) hematopoi-
etic stem cell transplantation (HSCT) is a curative
therapeutic option for older hematologic malignancy
patients as well as for younger patients with significant
comorbidities who are not candidates for high-
intensity myeloablative (MA) HSCT. However, there
is limited direct information regarding the impact of
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porting on RIC HSCT outcomes typically include
younger patients aged \60 years in their analyses
[11-13]. Hematologic malignancy patients\60 years
are often preferential candidates for MA HSCT, with
RIC HSCT reserved for those with impaired perfor-
mance status and/or significant comorbidities. There-
fore, the inclusion of patients aged\60 years in these
reports is a source of clinical heterogeneity, increases
bias, and hinders assessment of the impact of age on
RIC HSCT outcomes.
There is even less information on RICHSCT out-
comes in patients aged $65 years, the typical age for
Medicare coverage eligibility in the United States, a
priori it is possible that patients of such advanced age
have more aggressive disease biology, further impaired
physiologic reserve, increased treatment-related toxic-
ity, and worse RICHSCT outcomes even compared to
those aged\65 years. Assessing the clinical effective-
ness of RIC HSCT in this patient subgroup is there-
fore a priority, both to determine its clinical utility
and to justify the expenditure of limited health care re-
sources.
We undertook a retrospective study of consecutive
hematologic malignancy patients aged $60 years
treated with a consistent fludarabine/low-dose busul-
fan RIC HSCT regimen at the Dana-Farber Cancer
Institute. In additional analyses, we compared out-
comes in patient cohorts aged 60-64 years with those
aged $65 years, to directly assess for the impact of
advanced age on RIC HSCT outcomes.PATIENTS, MATERIALS, AND METHODS
Eligibility Criteria
Between January 2002 and June 2008, 158 consec-
utive hematologic malignancy patients aged$60 years
underwent adult donor RICHSCT at theDana Farber
Cancer Institute. Three patients underwent multiple
RIC transplants after relapsing; in these cases, only
the first transplant was used in the analysis. The
patients provided institutional review board (IRB)-
approved informed consent for data analysis.Patients, Conditioning Regimen, and Graft-
versus-Host Disease (GVHD) Prophylaxis
All patients received a consistent RIC regimen
comprising fludarabine (30 mg/m2 intravenously
[i.v.]) and once- or twice-daily busulfan (0.8 mg/kg
i.v.)  4 days. One hundred fifty-two patients (96%)
received peripheral blood stem cell infusions. GVHD
prophylaxis regimens included: (1) tacrolimus/
sirolimus 6 mini-methotrexate (93); (2) tacrolimus/
mini-methotrexate (50); (3) CD8 T cell depletion 1
tacrolimus/mini-methotrexate (3); and other (12).Tacrolimus and sirolimus were started on day 23,
with a goal to taper off by day 1180 in the absence of
GVHD. All patients received filgrastim at 5 mg/kg sub-
cutaneously (s.c.) daily, from day 11 until an absolute
neutrophil count (ANC) .1000 cells/mL; and a mini-
mum of 12 months of Pneumocystis jiroveci and herpes
simplex virus/varicella zoster virus (HSV/VZV) pro-
phylaxis. A preemptive treatment strategy with ganci-
clovir or valganciclovir was used if cytometalovirus
(CMV) reactivation was detected on routine monitor-
ing in the first 100 days after stem cell transplantation
(SCT). No preemptive or prophylactic donor lympho-
cyte infusions were given after HSCT.
Neutrophil and platelet engraftment was assessed
by the number of days to ANC$500/mL and platelets
$20,000/mL, respectively, in the absence of transfu-
sions. Unfractionated donor chimerism was assessed
from bone marrow aspirates and/or peripheral blood
at approximately day 130-45, and 3-4 months after
transplant. Genotype of donor and recipient were de-
termined using DNA extracted from pretransplant
samples, and percent donor chimerismwas determined
by analyses of informative short tandem repeat (STR)
loci using the ABI Profiler-Plus Kit (Applied Biosys-
tems Inc., Bedford, MA) and the ABI 310 Genetic
Analyzer. Acute GVHD (aGVHD) was assessed per
consensus grading [13].Statistical Analysis
Descriptive statistics was provided for patient
baseline characteristics. Two-sided Fisher’s exact test
was used to compare categoric variables between age
groups, and 2-sided Wilcoxon Rank-Sum test was
used to compare continuous variables between age
groups.
Cumulative incidence curves for grade II-IV
aGVHD and chronic GVHD (cGVHD) were con-
structed reflecting early death and death or relapse as
a competing risk, respectively. Cumulative incidence
curves for treatment-related death and relapse with or
without death were constructed reflecting time to re-
lapse and time to treatment related death as competing
risks. The difference between cumulative incidence
curves in the presence of a competing risk was tested
using the Gray method [14].
Time to relapse and time to nonrelapse death were
measured from the date of stem cell infusion. Patients
who were alive without relapse were censored at the
time last seen alive. Overall survival (OS) and progres-
sion-free survival (PFS) were calculated using the
Kaplan-Meier method. OS was defined as the time
from stem cell infusion to death from any cause. PFS
was defined as the time from stem cell infusion to re-
lapse, disease-progression, or death from any cause.
The log-rank test was used for the comparisons of
Kaplan-Meier curves, whereas the Gray test was used
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relapse mortality (NRM) and relapse. Prognostic
factors for OS and PFS were examined in Cox propor-
tional hazard models, whereas relapse and NRM were
examined in competing risks regression model [15].
Interactions between covariates were examined in the
Cox model and none was significant.RESULTS
Patient, Donor, and Transplant Characteristics
Peritransplant characteristics of the 158 patients
included in this study are shown in Table 1. The
median patient age was 63 years (range: 60-71 years).
Median follow-up time among survivors was 34.0
months (range: 12.0-85.7) post-HSCT. There were
106 male and 52 female patients. The principal
diseases were myeloid in 70% and lymphoid in 27%.
Seventy-six percent had high-risk disease (ie, acute
leukemia in relapse or greater than second complete
remission [CR2], MDS refractory anemia with exces-
sive blasts [RAEB] or secondary MDS, chronic mye-
logenous leukemia [CML] beyond first chronic phase
[CP1], lymphoma beyond first remission) and 12%
had received prior autologous transplantation.
Matched-unrelated (MUD), matched-related (MRD)
and 1-2 HLA locus (-A, -B, -C, -DRB1) mismatched
(MM) adult donors were used in 56%, 34%, and
10% of patients, respectively. The median stem cell
dose was 8.26 (range: 1.66-47.67)  106 CD341
cells/kg; and was not different between MUD/MM
versus MRD HSCT, at 8.39 (range: 2.35-47.67) 
106 CD341 cells/kg versus 8.05 (range: 1.66-23.18)
 106 CD341 cells/kg, respectively (P 5 .13).
For the cohort analysis, there were 110 patients
aged 60-64 years (median: 62 years; range: 60-64 years)
and 48 patients aged $65 years (median: 67 years;
range: 65-71 years). Themedian follow-up time among
survivors for the cohorts was 35.0 months (range: 12-
85.7) and 32.4 months (range: 12.7-72.8), respectively
(P5 .40). The cohorts did not differ significantly with
regard to covariates of patient sex, patient-donor sex
match, prior autologous transplant, donor stem-cell
source, disease risk at transplant, donor type
(matched-related, matched-unrelated, mismatched),
ECOG performance status at transplant, GVHD
prophylaxis regimen, year of transplant, donor CMV
status, and donor age (Table 1).
In this patient population aged $60 years, MUD
andMMdonors were more common thanMRD trans-
plants, at 104 and 54, respectively; and as expected, the
MUD/MM donors were significantly younger with
median age of 31 years (range: 18-59 years) versus
MRD median age of 59 years (range: 30-73 years)
(P # .0001). However, as noted before, the median
donor age was not different for patient cohorts of$65 years versus those aged 60-64 years. In addition,
there was no survival difference when OS and PFS
were examined by donor age categories of #30 years,
31-40 years; and .40 years.
Engraftment and Chimerism
The median time to neutrophil engraftment was
13 days (range: 2-70) in the 81 patients whose ANCna-
dired below 500 cells/mL. The median time to platelet
engraftment was 20 days (range: 11-78) in the 79
patients whose platelet-count nadired below 20,000
cells/mL. The median donor chimerism between 20
and 50 days after RIC HSCT was 94% (range:
3-100), and between 90 and 120 days after RIC
HSCT was 94% (range: 1-100). There was no clini-
cally relevant difference in time to neutrophil and
platelet engraftment between patients aged 60-64
years and those aged $65 years. Median time to neu-
trophil engraftment was 13 days (range: 2-70) in the
59 patients aged 60-64 years who experienced a nadir,
and 15 days (range: 3-33) in the 22 patients aged $65
years who experienced a nadir. The median time to
platelet engraftment was 20 days (range: 11-78)
in the 58 patients aged 60-64 years who experienced
a nadir and 19 days (range: 12-60) in the 21 patients
aged $65 years who experienced a nadir.
Survival, Disease Relapse, and NRM
The cumulative incidence of relapse (or progres-
sion) andNRM at 2 years was 54.6% and 10%. respec-
tively (Figure 1a).OS andPFS at 2 years was 46% (95%
confidence interval [CI], 38-54) and 35% (95% CI,
28-43), respectively (Figure 1b). When we compared
patients aged 60-64 years with those aged $ 65 years,
the cumulative incidence of relapse (or progression)
and NRM at 2 years was 53.5% versus 56.3%
(P 5 .31), and 10.5% versus 8.3% (P 5 .84), respec-
tively (Figure 2a). OS and PFS at 2 years were 49%
(95% CI, 39-58) versus 41% (95% CI, 26-54)
(P 5 .11), and 36% (95% CI, 27-45) versus 35%
(95% CI, 22-49) (P 5 .24), respectively (Figure 2b).
In both cohorts, early relapse was the primary cause
of treatment failure and death, with 100-day relapse/
progression rate of 27% versus 42% (P 5 .09) and
100-day mortality rate of 11% versus 27%, P 5 .02),
respectively.
GVHD
The maximum cumulative incidence of grade
II-IV aGVHD was 20.3%. Cumulative incidence of
cGVHD at 2 years was 45.9%. Comparing patients
aged 60-64 years with those aged $65 years, the max-
imum cumulative incidence of grade II-IV aGVHD
was 19.1% versus 22.9% (P 5 .52) respectively, and
cGVHD at 2 years was 51.8% versus 32.5%
(P5 .01) (Figure 2c and d). The higher early mortality
Table 1. Patient and Transplant Characteristics for the 158 Patients Aged $60 Years and for the Cohorts of Patients Aged 60-64
Years and $65 years, with Associated P-Values
Total (n 5 158) 60-64 years (n 5 110) $65 years (n 5 48)
P-Valuen % n % n %
Age, median (range) 63 (60, 71) 62 (60-64) 67 (65-71)
Donor age, median (range) 38 (18, 73) 39 (18, 66) 36 (19, 73) .87
Sex, M 106 67 73 66 33 69 .85
Patient-donor sex matching .5
MF 44 28 32 29 12 25
MM 62 39 41 37 21 44
FF 25 16 20 18 5 10
FM 27 17 17 15 10 21
Prior transplant 19 12 14 13 5 10 .79
Cell source .12
Bone marrow 5 3 5 5 — —
PBSC 152 96 105 95 47 98
Both BM and PBSC 1 1 — — 1 2
Diagnosis .42
ALL 3 2 2 2 1 2
AML 70 44 44 40 26 54
CLL,SLL,PLL 22 14 17 15 5 10
CML 5 3 4 4 1 2
MDS 28 18 17 15 11 23
Plasma cell disorder 3 2 2 2 1 2
MPD 8 5 7 6 1 2
NHL 18 11 16 15 2 4
Other acute leukemia 1 1 1 1 — —
Risk status 1
High risk 120 76 83 75 37 77
Low risk* 38 24 27 25 11 23
Donor type .85
MUD 89 56 61 55 28 58
MRD 54 34 37 34 17 35
Mismatched unrelated 14 9 11 10 3 6
Mismatched related 1 1 1 1 — —
ECOG performance status .78
0 45 28 30 27 15 34
1 65 41 46 42 19 40
2 16 10 10 9 6 13
Missing 32 20 24 22 8 17
aGVHD prophylaxis
Tacrolimus/Sirolimus ± mMTX 93 59 70 64 23 48 .18
Tacrolimus-mMTX (without Sirolimus) 50 32 32 29 18 38
CD8 T cell depletion + Tacrolimus/mMTX 3 2 2 2 1 2
Other 12 8 6 5 6 13
Donor CMV .71
No 109 69 75 68 34 71
Yes 47 30 34 31 13 27
Missing 2 1 1 1 1 2
Year of transplant, median (range) 2005 (2002-2008) 2005 (2002-2008) 2005 (2002-2008) .72
aGVHD indicates acute graft-versus-host-disease; M, male; F, female; MF, male donor-female recipient; MM, male donor-male recipient; FM, female
donor-male recipient; FF, female donor-female recipient; PBSC, peripheral blood stem cell; BM, bone marrow; ALL, acute lymphoblastic leukemia;
AML, acute myelogenous leukemia; CLL, chronic lymphocytic leukemia; SLL, small lymphocytic lymphoma; PLL, prolymphocytic leukemia; MDS, mye-
lodysplastic syndrome; MPD, myeloproliferative disease; NHL, non-Hodgkin lymphoma; MUD, matched unrelated donor; MRD, matched related donor;
CMV, cytomegalovirus; mMTX, mini-methotrexate.
*AML/ALL in first complete remission (CR1), CML in CP1, MDS with retinoic acid (RA) or retinoic acid receptors (RARS).
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the lower cGVHD rate in this cohort.Alternative Donors
Importantly, outcomes were not impaired in those
lacking an MRD. Two-year OS and PFS of MUD/
MM versus MRD HSCT was 52% (95% CI, 42-62)
versus 35% (95% CI, 22-47) (P 5 .10), and 43%
(95% CI, 33-53) versus 20% (95% CI, 11-32)(P 5 .006), respectively. With regard to advanced
age and donor outcomes, MUD/MM recipients aged
$65 years did not experience poorer outcomes com-
pared to those aged 60-64 years, with 2-year OS and
PFS of 50% (95% CI 31-67) versus 53% (95% CI,
41-64) (P 5 .69) and 45% (95% CI, 27-61) versus
43% (95% CI, 32-55) (P 5 .65), respectively. How-
ever, MRD recipients aged $65 years experienced
poorer 2-year OS, but not PFS, compared to those
aged 60-64 years, at 24% (95% CI, 7-45) versus 40%
































Figure 1. (a) Cumulative incidence of relapse and NRM as competing
risks for all patients aged $60 years. (b) Overall and progression-free
survival for all patients $60 years.
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versus 21% (95% CI, 10-36) (P 5 .19), respectively.Multivariate Models
We evaluated a competing risk regression model
for relapse and NRM incidence, including covariates
of diagnosis (AML/MDS versus non-AML/MDS),
disease-risk (high versus low), patient-donor sex
match (sex matched versus mismatched), donor type
(matched-related versus matched-unrelated or mis-
matched), patient age (dichotomized at age 65 years),
prior autologous transplant (yes versus no), year of
transplant (continuous variable), and GVHD prophy-
laxis (sirolimus containing versus not) (Table 2). Use
of sirolimus-based aGVHD prophylaxis was associ-
ated with reduced NRM (hazard ratio [HR] 5 0.29,
95%CI 0.10-0.80, p5 .02), and AML/MDS diagnosisat transplant was borderline associated with relapse
(HR 5 1.60, 95% CI 0.96-2.67, p 5 .07). Age of
$65 years was not associated with increased NRM
(HR5 0.72, 95%CI 0.21-2.47, P5 .60) nor increased
relapse incidence (HR5 1.14, 95% CI 0.70-1.87, P5
.60).
We also evaluated a multivariate cox model of
survival outcomes (PFS, OS), including covariates of
diagnosis (AML/MDS versus non-AML/MDS), dis-
ease-risk (high versus low), patient-donor sex match
(sex matched versus mismatched), donor type (MRD
versus MUD/MM), patient age (continuous variable,
or dichotomized at age 65 years), prior autologous
transplant (yes versus no), year of transplant (continu-
ous variable), and GVHD prophylaxis (sirolimus
containing versus not) (Table 3). Donor age and inter-
actions between covariates were examined, but none
were significant and were thus not included in the final
model. High-risk disease at transplant was associated
with poorer PFS (HR 5 2.10, 95% CI 1.23-3.58,
P 5 .01) and with poorer OS (HR 5 1.84, 95% CI
1.05-3.22, P 5 .03). AML/MDS diagnosis at trans-
plant (HR 5 1.66, 95% CI 1.04-2.66, 5 .03) and
MRD (HR 5 1.62, 95% CI 1.05-2.50, P 5 .03) were
associated with poorer PFS. However, age $65 years
was not associated with poorer PFS (HR 5 1.11,
95% CI 0.71-1.75, P 5 .64) or poorer OS (HR 1.32,
95% CI 0.83-2.10, P 5 .25).DISCUSSION
Hematologic malignancies are more frequent in
patients aged $60 years, and they have a worse prog-
nosis with chemotherapy compared with younger
adults. Most patients are not considered for RIC
HSCT, despite its tolerability and curative potential
in older patients with otherwise fatal hematologic can-
cers. For instance, at a major U.S. cancer center, de-
spite a protocol mandating that all AML patients
aged $50 years be evaluated by a HSCT physician
with a default plan for RIC HSCT in CR1 if they
had a matched related or unrelated donor, only 53 of
99 patients (54%) in CR actually underwent such an
evaluation. Of these, 26 patients had an HLA-matched
donor and 14 patients (14% of CR patients) underwent
RIC HSCT. Even within the cohort of patients aged
.50 years, the younger patients (\60 years) were sig-
nificantly more likely to be referred for HSCT evalu-
ation (P 5 .01) [16]. It is clear that for hematologic
malignancy patients aged $60 years, the likelihood
of receiving potentially curative RIC HSCT is mark-
edly low, despite their known dismal prognosis with
nontransplant therapy.
The underutilization of curative RIC HSCT may
be in part because of the limited data on transplant out-
comes in older patients. Very few analyses restricted to
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Figure 2. (a) Cumulative incidence of relapse and NRM as competing risks by age cohort. (b) Overall (A) and progression-free survival (B) by age co-
hort. (c) Cumulative incidence of grade II-IV acute GVHDby age cohort, with early death as a competing risk. (d) Cumulative incidence of chronic GVHD
by age cohort, with death/relapse as a competing risk.
Biol Blood Marrow Transplant 16:792-800, 2010 797RIC HSCT Outcomes in the Elderlypatients aged $60 years have been reported. Two
small retrospective analyses of 17 and 24 patients,
with limited median follow-ups of 13 months and 21
months, respectively, reported NRM of 33% and
25%, respectively, and OS of 29% at 1 year and 44%
at 2 years, respectively [17,18]. The limited sample
sizes precluded any assessment of the impact of the
advanced age of $65 years.
Prospective RICHSCTdata for patients aged$60
years are also limited. A small prospective trial utilizing
fludarabine-based RIC involving 19 AML/MDS
patients aged $60 years (median: 64 years; range:
60-70) and 27-month median follow-up has been
reported [19]. It indicated 1-year OS and PFS of68% and 61%, respectively. Another small trial with
fludarabine/low-dose total body irradiation (TBI)
RIC involving 32 hematologic malignancy patients
aged $60 years (median: 62 years; range: 60-70 years)
and a short 17-month median follow-up reported 1-
year NRM and relapse rates of 10% and 50%, respec-
tively, with OS and PFS of 53% and 43%, respectively
[20]. The 95% CIs of these estimates remain wide,
owing to limited sample size. An assessment of the
impact of advanced age of $65 years on RIC HSCT
outcomes remains unavailable, also likely because of
limited sample size. It therefore remains uncertain
whether patients aged $65 years experienced out-
comes similar to those of patients aged 60-64 years.
Table 2. Competing Risk Regression Model for NRM and Relapse Incidence (Year of Transplant as Continuous Covariate)
NRM Relapse
Variable HR 95% CI P HR 95% CI P
Age, $65 years versus 60-64 years 0.72 0.21 — 2.47 .6 1.14 0.70 — 1.87 .6
Prior transplant versus none 1.21 0.29 — 5.06 .79 1.02 0.51 — 2.04 .95
High risk versus low risk 4.85 0.72 — 32.70 .10 1.61 0.95 — 2.72 .08
Pt-donor sex, MF or FM versus MM or FF 1.32 0.48 — 3.63 .60 0.74 0.48 — 1.15 .18
Donor type, MRD versus MUD/MM 2.73 0.79 — 9.50 .11 1.27 0.80 — 1.99 .31
aGHVD prophylaxis, Siro containing versus not 0.29 0.10 — 0.80 .02 1.18 0.75 — 1.84 .47
Diagnosis, AML/MDS versus other 1.06 0.32 — 3.49 .93 1.60 0.96 — 2.67 .07
Year of transplant 1.00 0.72 — 1.40 .99 0.94 0.83 — 1.05 .27
NRM indicates nonrelapse mortality; CI, confidence interval; aGVHD, acute graft-versus-host-disease; M, male; F, female; MF, male donor-female
recipient; MM, male donor-male recipient; FM, female donor-male recipient; FF, female donor-female recipient; AML, acute myelogenous leukemia;
MDS, myelodysplastic syndrome; MUD, matched unrelated donor; MRD, matched related donor; CMV, cytomegalovirus; mMTX, minimethotrexate.
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Marrow Transplant Research (CIBMTR) retrospec-
tive analysis evaluating RIC HSCT outcomes in
AML/MDS patients aged$40 years has been reported
in abstract form [21]. Comparing patient cohorts aged
40-54 years, 55-60 years, 60-64 years, and $65 years,
the authors report that age was not significantly asso-
ciated with survival outcomes. As previously discussed,
the comparison of younger patients with those aged
$60 years is problematic and represents a source of
bias, as elderly patients aged $60 years likely have
more biologically aggressive disease than younger
patients. There is also further increased selection
bias because younger RICHSCT patients (who would
typically be candidates for MA HSCT) likely have
more comorbidities compared to the elderly patient
cohorts, that can confound survival outcomes as well
[22]. Additionally, inclusion of patients from multiple
centers, with intercenter variability with regard to pa-
tient referral, evaluation, selection, conditioning regi-
mens, GVHD prophylaxis, posttransplant care, and
data collection and reporting are additional sources
of heterogeneity and bias. It is therefore reassuring
that we also found no significant survival differences
between the 37 AML/MDS patients $65 years versus
the 61 patients aged 60-64 years, with 2-year OS andTable 3. Cox Model for PFS and OS-Adjusted Model (Year of Tran
OS
Variable HR 95% C
Age, $65 years versus 60-64 years 1.32 0.83 —
Prior transplant versus none 1.36 0.73 —
High risk versus low risk 1.84 1.05 —
Pt-donor sex, MF or FM versus MM or FF 0.89 0.58 —
Donor type, MRD versus MUD/MM 1.31 0.82 —
aGHVD prophylaxis, Siro containing versus not 0.8 0.52 —
Diagnosis, AML/MDS versus other 1.53 0.94 —
Year of transplant 0.97 0.85 —
CI indicates confidence interval; aGVHD, acute graft-versus-host-disease; M,
recipient; FM, female donor-male recipient; FF, female donor-female recipien
MUD, matched unrelated donor; MRD, matched related donor; OS, overall su
NB: The Cox model was repeated with and without inclusion of ECOG-PS, onc
a covariate; and none were significant.PFS of 39% versus 45% (P 5 .46) and 38% versus
27% (P 5 .82), respectively.
Our analysis also has important inherent limita-
tions. As a retrospective single-institution analysis, it
is susceptible to bias in patient selection, and the gen-
eralizability of our results to RIC HSCT outcomes at
other centers remains a question. We could not assess
the impact of comorbidities directly as routine HCT
comorbidity index scoring was only instituted recently
and is therefore unavailable for many patients in this
analysis. However, for all patients $60 years selected
for RIC HSCT, significant comorbidities were an
exclusionary factor per our consistent institutional
paradigm. We also cannot comment on RIC HSCT
outcomes in patients of more extreme age (ie, those
in their 70s and older), where additional data is re-
quired. The strength of this analysis is its primary
focus on elderly patients aged $60 years, all trans-
planted at a single center, with more consistent patient
referral, evaluation, and selection, as well as a consis-
tent RIC regimen, GVHD prophylaxis and posttrans-
plant monitoring. Such consistency also improves the
comparability between patients aged 60-64 years and
those aged $65 years.
Our data indicate that for appropriately selected
patients aged $60 years, RIC HSCT is well toleratedsplant as Continuous Covariate)
PFS
I P HR 95% CI P
2.1 .25 1.11 0.71 — 1.75 .64
2.53 .33 1.23 0.69 — 2.21 .49
3.22 .03 2.1 1.23 — 3.58 .01
1.35 .58 0.8 0.54 — 1.19 .26
2.08 .26 1.62 1.05 — 2.5 .03
1.24 .32 0.86 0.57 — 1.3 .47
2.51 .09 1.66 1.04 — 2.66 .03
1.1 .63 0.96 0.86 — 1.08 .52
male; F, female; MF, male donor-female recipient; MM, male donor-male
t; AML, acute myelogenous leukemia; MDS, myelodysplastic syndrome;
rvival; PFS, progression-free survival.
e- versus twice-daily busulfan conditioning, and CD34+ stem cell dose as
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with acute grade II-IV and cGVHD rates of 19.6%
and 45.9% at 200 days and 2 years, respectively. In
this elderly hematologic malignancy population, sur-
vival after RIC HSCT was reasonable, especially for
these otherwise fatal illnesses, with a 2-year OS and
PFS of 46% and 35%, respectively. Importantly,
RIC HSCT outcomes for patients lacking matched-
related donors (as is common in older patients) were
not impaired. As in younger patients, early relapse is
a major cause of death. Novel approaches to reduce
relapse (eg, vaccine-based strategies to boost immuno-
logic graft-versus-tumor effect [23]) without increas-
ing GVHD remain a priority.
Specifically with regard to the impact of advanced
age, patients aged $65 years did not experience
impaired engraftment or greater treatment-related
toxicity (NRM, GVHD), and their survival was com-
parable to patients aged 60-64 years. These findings
are also concordant with the preliminary results, re-
ported in abstract form, of a multicenter retrospective
analysis of hematologic malignancy patients aged$60
years, wherein advanced age was not associated with
poorer outcomes after RIC HSCT [24].
In summary, our analysis indicates that RIC SCT
is a viable treatment option for appropriately selected
hematologic malignancy patients aged $60 years.
Although early disease relapse remains problematic,
GVHD and NRMwere acceptable and did not appear
to increase with advancing age. Indeed, advanced
disease at time of transplant and a diagnosis of AML/
MDS, but not advanced age, were associated with
poorer survival. Advanced age should not be the basis
for excluding hematologic malignancy patients from
potentially curative RIC HSCT.ACKNOWLEDGMENTS
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